Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis and management of secondary-progressive multiple sclerosis: time for change.
Oh J, Alikhani K, Bruno T, Devonshire V, Giacomini PS, Giuliani F, Nakhaipour HR, Schecter R, Larochelle C. Oh J, et al. Among authors: devonshire v. Neurodegener Dis Manag. 2019 Dec;9(6):301-317. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26. Neurodegener Dis Manag. 2019. PMID: 31769344 Free article. Review.
Impact of multiple sclerosis relapses on progression diminishes with time.
Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Tremlett H, et al. Among authors: devonshire v. Neurology. 2009 Nov 17;73(20):1616-23. doi: 10.1212/WNL.0b013e3181c1e44f. Epub 2009 Nov 4. Neurology. 2009. PMID: 19890070 Free PMC article.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Devonshire V, et al. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Lancet Neurol. 2012. PMID: 22494956 Clinical Trial.
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, Hellwig K, Hutton GJ, McCombe P, Moore M, Rog D, Schneider JR, Simm RF, Sousa L, Vincent SG, Chung L, Daizadeh N, Mitchell C, Compston DAS; CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Oh J, et al. Among authors: devonshire v. Mult Scler Relat Disord. 2020 Aug;43:102146. doi: 10.1016/j.msard.2020.102146. Epub 2020 May 6. Mult Scler Relat Disord. 2020. PMID: 32498033 Free article. Clinical Trial.
70 results